Charting the Course: Sequencing Immunotherapy for Multiple Myeloma
American Society of Clinical Oncology Educational Book · 2024
DOI: 10.1200/edbk_432204 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2024. Verfasst von Meera Mohan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 123 Literaturangaben.
Abstract (Originalsprache)
Multiple chimeric antigen receptor (CAR) T-cell and bispecific antibody (bsAb) therapies have been approved, demonstrating impressive clinical efficacy in relapsed/refractory multiple myeloma (MM). Currently, these treatment share overlapping approval indications in the relapsed/refractory space, highlighting the importance of optimal selection and sequencing to maximize clinical efficacy. For patients previously unexposed to T-cell–directed therapies, several factors should be weighed when both options are available. These factors include access and logistical challenges associated with CAR T-cell therapy, disease-specific factors such as tempo of disease relapse, in addition to patient-specific factors such as frailty, and distinct toxicity profiles across these agents. Sequential therapy, whether it involves CAR T-cell therapy followed by bsAb or vice versa, has demonstrated clinical efficacy. When sequencing these agents, it is crucial to consider various factors that contribute to treatment resistance with careful selection of treatments for subsequent therapy in order to achieve favorable long-term patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
- Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.
- Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Zitieren
APA
Mohan, M., Van Oekelen, O., Akhtar, O. S., Cohen, A., & Parekh, S. (2024). Charting the Course: Sequencing Immunotherapy for Multiple Myeloma. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk_432204
Vancouver
Mohan M, Van Oekelen O, Akhtar OS, Cohen A, Parekh S. Charting the Course: Sequencing Immunotherapy for Multiple Myeloma. American Society of Clinical Oncology Educational Book. 2024. doi:10.1200/edbk_432204
BibTeX
@article{Mohan2024,
author = {Mohan, Meera and Van Oekelen, Oliver and Akhtar, Othman Salim and Cohen, Adam and Parekh, Samir},
title = {Charting the Course: Sequencing Immunotherapy for Multiple Myeloma},
journal = {American Society of Clinical Oncology Educational Book},
year = {2024},
doi = {10.1200/edbk_432204}
}
EUVIMED